James J. Doherty - 01 Feb 2024 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Employee Stock Option (right to buy)	Award	$0	+601,000		$0.000000	601,000	01 Feb 2024	Common Stock	601,000	$3.11	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on February 1, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date.